nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

29.01.2018 | Original Article

Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study

verfasst von: Ravisha Wadhwa, Manoj Kumar, Yam Nath Paudel, Ramsha Iqbal, Priyanka Kothari, Ritu Trivedi, Divya Vohora

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

In view of the opposite effects of gut and brain serotonin in bone, the key role of Wnt β/catenin pathway in osteoblastic proliferation and the controversial bony effects of selective serotonin reuptake inhibitors antidepressants, the present study investigated the effects of escitalopram alone and in combination with carbidopa (to block gut-derived serotonin) on markers of bone turnover and Wnt signaling and micro-CT in male Wistar rats. Escitalopram (2.0 mg/kg, p.o.) and carbidopa (10 mg/kg, p.o.) were administered daily for 40 days following which indicators of reduced (dickkopf-1, sclerostin), and increased (alkaline phosphatase) bone formation and bone resorption markers (receptor activator of nuclear factor κB ligand, tartrate-resistant acid phosphatase 5b) were determined. Our results indicated that escitalopram adversely affected bone as indicated by reduced bone formation and enhanced bone resorption. Further, the effects of escitalopram on bone formation were possibly mediated through gut serotonin while the mechanisms responsible for effects on resorption seem unrelated to gut serotonin. The promising effects of carbidopa on bone formation, as observed in our study, open up exciting possibilities for this drug requiring further investigations.

Dubnov-Raz G, Hemila H, Vurembrand Y, Kuint J, Maayan-Metzgar A (2012) Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density. Early Hum Dev 88:191–194CrossRefPubMed

Diem SJ, Joffe H, Larson JC, Tsai JN, Guthrie KA, LaCroix AZ, Ensrud KE, Freeman EW, Leder BZ (2014) Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab 99:E1732–E1737CrossRefPubMedPubMedCentral

Battaglino R, Vokes M, Schulze-Spate U, Sharma A, Graves D, Kohler T, Muller R, Yoganathan S, Stashenko P (2007) Fluoxetine treatment increases trabecular bone formation in mice (fluoxetine affects bone mass). J Cell Biochem 100:1387–1394CrossRefPubMed

Goltzman D (2011) LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res 26:1997–2001CrossRefPubMed

Radaei F, Gharibzadeh S (2013) The effect of carbidopa in carbidopa-levodopa combination on reducing osteoporotic symptoms in Parkinson’s disease patients. Brain Disord Ther 2:2

Westendorf JJ, Kahler RA, Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341:19–39CrossRefPubMed

Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635–2643CrossRefPubMed

Glinka A, WuW Delius H, Monaghan AP, Blumenstock C, Niehrs C (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391:357–362CrossRefPubMed

Goodwin GM, Green AR (1985) A behavioural and biochemical study in mice and rats of putative selective antagonists of 5-HT₁ and 5-HT₂ receptors. Br J Pharmacol 84:743–753CrossRefPubMedPubMedCentral

10.

Bourke CH, Capello CF, Rogers SM, Yu ML, Boss-Williams KA, Weiss JM, Stowe ZN, Owens MJ (2013) Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. Psychopharmacology 228:231–241CrossRefPubMedPubMedCentral

11.

Smarius LJ, Jacobs GE, Hoeberechts-Lefrandt DH, Kam ML, Van der Post JP, Rijk R, Van Pelt J, Schoemaker RC, Zitman FG, Van Gerven JM, Gijsman HJ (2008) Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. J Psychopharmacol 22:426–433CrossRefPubMed

12.

Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U (2008) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 80:490–494CrossRefPubMed

13.

Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248–2253CrossRefPubMed

14.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin Phenol reagent. J Biol Chem 193:265–275PubMed

15.

Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ (2008) RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 23:672–682CrossRefPubMed

16.

Tenniswood M, Bird CE, Clark AF (1976) Acid phosphatase: androgen dependent markers of rat prostate. Can J Biochem 54:350–357CrossRefPubMed

17.

Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135:825–837CrossRefPubMedPubMedCentral

18.

Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976–989CrossRefPubMedPubMedCentral

19.

Zhang W, Drake MT (2012) Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Curr Osteoporos Rep 10:93–100CrossRefPubMed

20.

Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56:42–47CrossRefPubMed

21.

Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P (2010) Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 16:308–312CrossRefPubMedPubMedCentral

22.

Ducy P, Karsenty G (2010) The two faces of serotonin in bone biology. J Cell Biol 191:7–13CrossRefPubMedPubMedCentral

23.

Garfinkel PE, Warsh JJ, Stancer HC, Godse DD (1977) CNS monoamine metabolism in bipolar affective disorder. Evaluation using a peripheral decarboxylase inhibitor. Arch Gen Psychiatry 34:735–739CrossRefPubMed

24.

Yamada J, Sugimoto Y, Ujikawa M (1999) The serotonin precursor 5-hydroxytryptophan elevates serum leptin levels in mice. Eur J Pharmacol 383:49–51CrossRefPubMed

25.

Lee DJ, Tseng HC, Wong SW, Wang Z, Deng M, Ko CC (2015) Dopaminergic effects on in vitro osteogenesis. Bone Res 3:15020CrossRefPubMedPubMedCentral

26.

Inose H, Zhou B, Yadav VK, Guo XE, Karsenty G, Ducy P (2011) Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res 26:2002–2011CrossRefPubMed

27.

Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, Slørdahl K, Tamburstuen MV, Reseland JE, Syversen U (2006) Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98:139–151CrossRefPubMed

28.

Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618–625CrossRefPubMed

29.

Halleen JM, Alatal SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337–1345CrossRefPubMed

Titel: Effect of escitalopram and carbidopa on bone markers in Wistar rats: a preliminary experimental study
verfasst von: Ravisha Wadhwa
Manoj Kumar
Yam Nath Paudel
Ramsha Iqbal
Priyanka Kothari
Ritu Trivedi
Divya Vohora
Publikationsdatum: 29.01.2018
Verlag: Springer Japan
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 1/2019
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-018-0908-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Differential osteopontin expression in human osteoblasts derived from iliac crest and alveolar bone and its role in early stages of angiogenesis

Diffuse idiopathic skeletal hyperostosis is associated with lumbar spinal stenosis requiring surgery

Relationship between melatonin and bone resorption rhythms in premenopausal women

Regulatory mechanisms of sclerostin expression during bone remodeling

Short-term and long-term effects of osteoporosis on incisor teeth and femoral bones evaluated by Raman spectroscopy and energy dispersive X-ray analysis in ovariectomized rats

Does Trabecular Bone Score (TBS) improve the predictive ability of FRAX® for major osteoporotic fractures according to the Japanese Population-Based Osteoporosis (JPOS) cohort study?